Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mastermind-like (MAML) proteins, including MAML1, MAML2, and MAML3, are a family of transcriptional coactivators essential for the canonical Notch signaling pathway. Upon ligand binding, the Notch intracellular domain (NICD) translocates to the nucleus, where it binds the DNA-binding protein RBPJ (CSL) and recruits MAML to form a stable, active tripartite transcription complex. This complex subsequently recruits other coactivators, such as p300, to initiate the transcription of Notch target genes involved in cell fate determination, proliferation, and survival. Beyond Notch signaling, MAML proteins also function as coactivators in other major pathways, including Wnt/beta-catenin, Sonic Hedgehog, Hippo, and NF-kB.
Dysregulation of MAML proteins is strongly implicated in various human malignancies, such as T-cell acute lymphoblastic leukemia (T-ALL), breast cancer, and mucoepidermoid carcinoma, where recurrent MAML2 gene fusions (e.g., CRTC1-MAML2) act as oncogenic drivers. Consequently, MAML has emerged as an attractive therapeutic target. Pharmacological strategies to inhibit MAML include stapled peptides like SAHM1, which mimic dominant-negative MAML to block the assembly of the Notch transcription complex, and small molecules like IMR-1 that prevent MAML recruitment to chromatin. While targeting MAML offers a way to bypass the resistance and some toxicities associated with upstream gamma-secretase inhibitors, potential safety concerns include gastrointestinal toxicity, impaired myogenesis, and immune system disruption.
Inhibition of the assembly of the Notch transcriptional activation complex (NTC) by disrupting the interaction between Mastermind-like (MAML) proteins, the Notch intracellular domain (NICD), and the DNA-binding protein RBPJ (CSL).
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mastermind-like protein (MAML).